| Literature DB >> 33672674 |
Raúl López-Fernández-Sobrino1, Jorge R Soliz-Rueda1, Maria Margalef1, Anna Arola-Arnal1, Manuel Suárez1, Francisca I Bravo1, Begoña Muguerza1.
Abstract
Wine lees (WL) are by-products generated in the winemaking process. The aim of this study was to investigate the angiotensin-converting enzyme inhibitory (ACEi) activity, and the blood pressure (BP) lowering effect of WL from individual grape varieties. The relationship among their activities and phenolic profiles was also studied. Three WL, from Cabernet, Mazuela, and Garnacha grape varieties, were firstly selected based on their ACEi properties. Their phenolic profiles were fully characterized by UHPLC-ESI-Q-TOF-MS. Then, their potential antihypertensive effects were evaluated in spontaneously hypertensive rats (SHR). BP was recorded before and after their oral administrations (2, 4, 6, 8, 24, and 48 h) at a dose of 5 mL/kg bw. Cabernet WL (CWL) exhibited a potent antihypertensive activity, similar to that obtained with the drug Captopril. This BP-lowering effect was related to the high amount of anthocyanins and flavanols present in these lees. In addition, a potential hypotensive effect of CWL was discarded in normotensive Wistar-Kyoto rats. Finally, the ACEi and antihypertensive activities of CWL coming from a different harvest were confirmed. Our results suggest the potential of CWL for controlling arterial BP, opening the door to commercial use within the wine industry.Entities:
Keywords: Cabernet grape variety; SHR; blood pressure; hypertension; polyphenols; winery by-product
Mesh:
Substances:
Year: 2021 PMID: 33672674 PMCID: PMC7924335 DOI: 10.3390/nu13020679
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717